it all comes down to trust, which this management team and BOD hasnt earned with investors or the street. I agree this was an overreaction but MM's love this stock. they are making money hand over fist.
what did you mean by "My belief was that the pancreatic trial was too early to project any benefit." Also, it appeared bavi was "active" with pancreatic so could it just finding the right combo? And what's your take on the ecog handicap with such a small trial?